# US 2021/0330780 A1 · Recombinant vector for expressing virus-like particles in plant and method for preparation of vaccine composition containing circovirus-like particles by using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330780 A1
- Document ID: US20210330780A1
- Status: Published application
- Kind: A1
- Application number: 17/320,369
- Filed: 2021-05-14
- Published: 2021-10-28
- Earliest claimed: 2018-11-15
- Assignees: Bioapplications Inc.
- Applicants: Bioapplications Inc.
- Inventors: Eun-Ju Sohn; Yongjik Lee; Sangmin Lee
- Web page: https://patentgrep.com/patent/US20210330780A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/12: Antivirals
- C07K 14/005: from viruses
- C07K 14/415: from plants
- C12N 15/8205: {Agrobacterium mediated transformation}
- C12N 15/8221: {Transit peptides}
- C12N 15/8257: {for the production of primary gene products, e.g. pharmaceutical products, interferon}
- A61K 2039/55505: {Inorganic adjuvants}
- C07K 2319/02: containing a signal sequence
- C12N 2750/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/10023: Virus like particles [VLP]
- C12N 2750/10034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2750/10051: Methods of production or purification of viral material
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a technique of preparing a vaccine composition from PCV2 isolated from a plant transformed with a chlorophyll-targeting recombinant vector for expression in plants and provides a recombinant vector carrying a polynucleotide coding for a recombinant protein in which a chlorophyll-targeting protein and a PCV2 capsid protein are fused to each other. In addition, provided are a transgenic plant transformed with the recombinant vector, a method for isolating and purifying a target protein from the transgenic plant, a method for preparing a vaccine composition containing virus-like particles by using same, and a vaccine composition prepared by the preparation method.

## Claims

### Claim 1

A recombinant vector for plant expression, comprising a polynucleotide encoding a RuBisCO transit peptide comprising an amino acid sequence represented by SEQ ID NO: 1 and a polynucleotide encoding a porcine circovirus type 2 (PCV2) capsid protein comprising an amino acid sequence represented by SEQ ID NO: 3 or 5.

### Claim 2 (depends on 1)

The recombinant vector of claim 1, wherein the polynucleotide encoding the RuBisCO transit peptide comprises a base sequence represented by SEQ ID NO: 2, and the polynucleotide encoding the PCV2 capsid protein comprises a base sequence represented by SEQ ID NO: 4 or 6.

### Claim 3 (depends on 1)

The recombinant vector of claim 1, further comprising a polynucleotide encoding a polyhistidine-tag comprising an amino acid sequence represented by SEQ ID NO: 7.

### Claim 4 (depends on 3)

The recombinant vector of claim 3, wherein in the recombinant vector, a polynucleotide encoding a RuBisCO transit peptide, a polynucleotide encoding a polyhistidine-tag, and a polynucleotide encoding a PCV2 capsid protein are sequentially connected between a promoter and a terminator.

### Claim 5 (depends on 1)

A transgenic plant transformed with the recombinant vector of claim 1.

### Claim 6 (depends on 1)

A method for preparing a vaccine composition containing virus-like particles, the method comprising the following steps: (S1) transforming a plant using the recombinant vector of claim 1; (S2) isolating and purifying a PCV2 capsid protein from the transgenic plant obtained in Step (S1); (S3) making the PCV2 capsid protein obtained in Step (S2) into virus-like particles; and (S4) preparing a vaccine composition containing the virus-like particles obtained in Step (S3).

### Claim 7 (depends on 26)

The method of claim 26, wherein the protein extraction buffer solution comprises 10 to 100 mM Tris, 100 to 300 mM sodium chloride (NaCl), 0.01 to 0.5% Triton X-100(polyethylene glycol p-(1,1,3,3-tetramethylbutyl)-phenylether, and 5 to 300 mM imidazole.

### Claim 8 (depends on 26)

The method of claim 26, wherein the agarose is nickel-nitrilotriacetic acid (Ni-NTA) agarose.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 6)

The method of claim 6, further comprising adding an adjuvant.

### Claim 13 (depends on 6)

The method of claim 6, wherein the plant is a dicotyledonous plant selected from the group consisting of Arabidopsis thaliana, soybean, tobacco, eggplant, capsicum, potato, tomato, Chinese cabbage, cabbage, and lettuce; or a monocotyledonous plant selected from the group consisting of rice, barley, wheat, rye, corn, sugar cane, oats, and onion.

### Claim 14 (depends on 6)

The method of claim 6, wherein Step (S1) transforms a plant using a bacterium into which a recombinant vector is introduced.

### Claim 15 (depends on 14)

The method of claim 14, wherein the bacterium is Agrobacterium tumefaciens.

### Claim 16 (depends on 6)

The method of claim 6, wherein Step (S3) makes virus-like particles by changing a pH of a buffer solution including a PCV2 capsid protein.

### Claim 17 (depends on 16)

The method of claim 16, wherein the buffer solution comprises 50 to 100 mM Tris, 300 to 1000 mM sodium chloride (NaCl), and 10 to 100 mM arginine, and has a pH of 6.9 to 7.5.

### Claim 18 (depends on 17)

The method of claim 17, wherein the pH is 7.2.

### Claim 19 (depends on 6)

The method of claim 6, wherein the vaccine composition prevents porcine circovirus infection.

### Claim 20 (depends on 19)

The method of claim 19, wherein the vaccine composition further comprises an adjuvant.

### Claim 21 (depends on 20)

The method of claim 20, wherein the adjuvant is alum.

### Claim 22 (depends on 6)

The method of claim 6, wherein the virus-like particles are shown to have a molecular weight of 1,800 kDa or more and 2,200 kDa or less by size-exclusion chromatography and 669 kDa or more by polyacrylamide gel electrophoresis (Native-PAGE), and are a spherical or ring form having a diameter of 20 nm to 30 nm when stained by a negative staining method, and then observed by a transmission electron microscope.

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26 (depends on 6)

The method of claim 6, wherein step (S2) isolates and purifies the PCV2 capsid protein using a method that comprises the following steps: (P1) preparing a plant mixture solution by mixing the transgenic plant obtained in Step (S1) with a protein extraction buffer solution; (P2) adsorbing a recombinant protein in which a polyhistidine-tag is linked to the PCV2 capsid protein by injecting the mixture solution obtained in Step (P1) into a column packed with agarose; (P3) washing the column by injecting a washing solution into the column; and (P4) eluting the recombinant protein adsorbed onto agarose by injecting an elution solution into the column.
